The biggest gift teplizumab gives us is time—just time being a normal kid
For the first time in the history of type 1 diabetes treatment, the NHS in England and Wales has approved a drug that does not cure the condition but does something almost as precious — it postpones it. Teplizumab, an immunotherapy delivered by infusion over fourteen days, intervenes at the moment the immune system has begun its quiet destruction of insulin-producing cells, buying patients up to three years before the full weight of lifelong insulin management descends. It is a milestone that reframes the medical relationship with this disease: from one of management after the fact, to one of intervention before the storm arrives. The horizon it points toward — personalized immunotherapy combinations that might one day eliminate insulin dependency entirely — suggests this approval is less an endpoint than a first step.
- A drug that can delay type 1 diabetes by three years has been approved for NHS use, offering children and young adults a window of ordinary life before insulin becomes a daily necessity.
- The treatment carries a critical constraint: it must be given before symptoms appear, meaning patients must first be identified as at-risk — a screening infrastructure the UK does not yet have in place.
- Around 1,100 patients are expected to be eligible in the first year, but many more children who could benefit will likely never know they qualify until the opportunity has already passed.
- Families who have accessed the drug describe the fourteen-day hospital infusion as demanding, but the reward — years of normalcy for their child — as beyond measure.
- With multiple immunotherapy treatments now in development, researchers and charities envision a future where personalized drug combinations could remove insulin dependency from type 1 diabetes entirely.
For the first time, the NHS in England and Wales is offering a drug that can delay the onset of type 1 diabetes by up to three years. Teplizumab is an immunotherapy administered through a hospital infusion over fourteen consecutive days. It works by intervening before symptoms appear, at the moment the immune system has begun attacking insulin-producing cells but the patient still feels well.
Type 1 diabetes arrives without warning and without mercy. Once it takes hold, a person must monitor blood glucose constantly, calculate every meal, and inject insulin multiple times daily for the rest of their life. For children like eight-year-old Theo, diagnosed at four, this means no switching off — a relentless arithmetic of food, insulin, and risk that his mother Vicky navigates every single day.
Teplizumab offers something different: delay. NICE called the decision genuinely exciting. Around 1,100 patients could be eligible in the first year, at a published cost of approximately £150,000 per course, though the NHS negotiated a confidential discount with manufacturer Sanofi.
The drug's central limitation is also its defining challenge. It only works before symptoms develop, which requires identifying at-risk patients through blood testing. The UK has no national screening programme for this — Italy is the only country in the world that does. Most people in Britain discover their risk by accident, meaning many children who could benefit will never know in time.
Dima's family learned of his risk through a cousin's diagnosis. His mother Elena enrolled him in early compassionate access before formal approval. She describes the infusion course as hard work, but the reward — time for her son to simply be a child — as immeasurable. "The biggest gift teplizumab gives us is time," she says.
The approval signals a broader shift in how medicine approaches this disease. Several other immunotherapy treatments are now in development, and the long-term vision is striking: future patients may receive personalized drug combinations and never become dependent on insulin at all. For now, teplizumab offers something more modest but no less significant — a reprieve, measured in years, from a condition that otherwise offers none.
For the first time, the NHS in England and Wales is offering a drug that can buy time—three years of it—before type 1 diabetes forces a child or young adult into the daily machinery of insulin management. The drug is called teplizumab, an immunotherapy delivered through a vein as a hospital infusion over fourteen consecutive days. It works by intervening before symptoms appear, targeting the moment when the immune system has begun attacking the insulin-producing cells in the pancreas but the person still feels well.
Type 1 diabetes strikes without warning. It can develop at any age, though early teenage years are most common. When it arrives, it arrives completely: the body stops making insulin, and from that moment forward, a person must monitor their blood glucose constantly, calculate carbohydrates at every meal, and inject or pump insulin multiple times daily for the rest of their life. For a child, this means no switching off. Vicky, mother of eight-year-old Theo, who was diagnosed at four, describes the arithmetic of breakfast: weighing food, counting carbohydrates, calculating the right insulin dose. If blood sugar drops too low, it becomes a medical emergency. If it stays high, it damages blood vessels and nerves. The condition is relentless.
Teplizumab offers something different: delay. The National Institute for Health and Care Excellence, which advises the NHS on which medicines to fund, called the decision "genuinely exciting." Around 1,100 patients could be eligible in the first year, with roughly 820 per year in the longer term once the initial surge of demand clears. The published price is approximately £150,000 per course, though the NHS negotiated a confidential discount with manufacturer Sanofi.
But there is a catch. The drug only works if given before symptoms develop, which means patients must first be identified as at-risk through blood testing. Italy is the only country in the world with a national screening programme for this purpose. In the UK, routine testing is not yet available on the NHS. Most people discover they are at risk by accident—through blood tests for other reasons, or because a family member has the condition. This means many children who could benefit will never know they need the drug until it is too late.
Dima's family found out through his cousin's diagnosis. His mother Elena signed him up for early access on compassionate grounds before the drug was formally approved. She describes the fourteen-day infusion course as "hard work," but the payoff, she believes, is immeasurable: time for her son to be a normal child, living a normal life, before insulin becomes necessary. "The biggest gift teplizumab gives us is time," she says. For families managing type 1 diabetes, time is the scarcest resource.
The approval marks a turning point in how medicine approaches the disease. Breakthrough T1D, the charity that funded research leading to teplizumab's development, notes that several other immunotherapy treatments are now in development. The long-term vision is striking: future patients might receive personalized combinations of these drugs and never become dependent on insulin at all. For now, teplizumab offers something more modest but no less significant—a reprieve, measured in years, from a condition that otherwise offers none.
Citas Notables
It's something which you can never switch off from. When you make breakfast, you've got to weigh everything, counting how many carbohydrates are in it, so that you know the right amount of insulin to give.— Vicky, mother of Theo, describing daily management of type 1 diabetes
The biggest gift teplizumab gives us is time—just time being a normal kid, living a normal life.— Elena, mother of Dima, on what the drug's delay means for her son
La Conversación del Hearth Otra perspectiva de la historia
Why does this drug need to be given before symptoms show up? Can't you just give it once someone is diagnosed?
Because by the time symptoms appear, the immune system has already destroyed most of the insulin-producing cells. The drug works by stopping the immune attack before it goes too far. Once you're symptomatic, there's not much left to save.
So you need a blood test to know you're at risk, but the NHS doesn't routinely screen for it. How do people find out?
Mostly by accident. A blood test for something else, or because a relative has it. Italy screens everyone, but they're alone in that. In the UK, you're relying on luck or family history.
If this drug delays onset by three years, what happens after those three years?
You still develop type 1 diabetes. You still need insulin. But you've had three extra years of childhood without the daily burden—no carb counting, no blood checks, no injections. For a family, that's enormous.
The price is £150,000. Is that sustainable for the NHS?
They negotiated a discount, so the actual cost is lower. And they're estimating around 820 patients per year long-term. It's expensive, but they've decided it's worth it.
You mentioned other drugs in development. Could those actually prevent diabetes entirely?
That's the hope. If you could combine multiple immunotherapies, you might stop the immune attack completely and never need insulin. But that's years away.
What's the hardest part for families right now?
Not knowing. Most children with type 1 diabetes have no family history. You can't screen for it routinely. So you don't know your child is at risk until they're already sick.